PORT WASHINGTON, N.Y.–New Brunswick Scientific, an Eppendorf Company (Edison, NJ, www.nbsc.com), and Pall Corporation (Port Washington, NY, www.pall.com) today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

“This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect.”

The joint effort will build on the capabilities of Pall’s Allegro™ single-use biocontainer platform and New Brunswick’s CelliGen® bioprocess controller, to better serve upstream applications ranging from the process development laboratory to the full-scale cGMP production suite.

This partnership combines the historic market strengths of the two companies in upstream biopharmaceutical processing, strengths that have been recently augmented by New Brunswick Scientific’s development of the CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall’s acquisition of MicroReactor Technologies and the Micro-24 microbioreactor.

According to Mike Sattan, New Brunswick’s Vice President Marketing, “This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect.”

Ken Frank, President Pall Life Sciences Biopharmaceuticals, said, “We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications. We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.”

About New Brunswick Scientific

New Brunswick Scientific’s (NBS) headquarters is based in Edison, N.J. USA, with sales and distributor offices located worldwide. Founded in 1946, NBS is a leading manufacturer of innovative equipment for culture growth, detection and storage. The company offers a broad range of cell culture bioreactors, including stirred-tank and packed-bed bioreactors in 1 – 3,000 liter capacities, as well as their new single-use bioreactor, the CelliGen BLU, introduced earlier this year. Biological shakers, fermentors, CO2 incubators and ultra-low temperature freezers round out their product line.

About Pall Corporation

Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The company’s engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees serving customers worldwide. Pall has been named a top “green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, visit www.pall.com/green.